Biora Therapeutics Inc BIORQ

$0.00 0.00 (—)

Valuation

Market cap
0
Revenue TTM
$0
Net income TTM
$-124,120,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
-0.18

Trading

Volume
1,000
Avg volume
—
Day's range
$0.00 – $0.00
Shares out
4,523,000
Stochastic %K
50%
Beta
2.42
Analysts
Strong Buy
Price target
$45.00

Price

Company profile

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of l...

Show more

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On May 27, 2025, the voluntary petition of Biora Therapeutics, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on December 27, 2024.

Industry
Biotechnology
Sector
Healthcare
Phone
833 727 2841
Website
https://www.bioratherapeutics.com
Address
4330 La Jolla Village Drive, Suite 300, San Diego, United States

Latest news

No headlines yet.